Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-11-25
2011-10-18
Jarrell, Noble (Department: 1622)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S016000
Reexamination Certificate
active
08039480
ABSTRACT:
The invention relates to substituted carbo- and heterocyclic spiro compounds of the formula Ia which inhibit thiol proteases, to processes for their preparation and to the use thereof as medicaments.
REFERENCES:
patent: 6720319 (2004-04-01), Liu et al.
patent: 0621267 (1994-10-01), None
patent: WO 99/24460 (1999-05-01), None
patent: WO 00/55125 (2000-09-01), None
patent: WO 2004/052921 (2004-06-01), None
patent: WO 2005/040142 (2005-05-01), None
Wu et al. Bioorganic and Medicinal Chemistry Letters, 2006, 16, pp. 3674-3678.
Bromme, D.: et al.,, Human Cathepsin O2, A Matrix Protein-Degrading Cysteine Protease Expressed in Osteoclasts, The Journal of Biological Chemistry, vol, 271, No. 4, (1996), pp. 2126-2132.
Grabowska, U. B., et. al., Recent Developments in Cathepsin K Inhibitor Design, Curr. Opin. Drug Disc, Dev., vol. 8, No. 5, pp. 619-630, (2005).
Hou, W.-S., et. al., Cathepsin K is a Critical Protease in Synovial Fibroblast-Mediated Collagen Degradation, American Journal of Pathology, vol. 159, No. 6, (2001), pp. 2167-2177.
Kim, W., et. al., Recent Developments of Cathepsin Inhibitors and Their Selectivity, Expert Opin. Ther. Patents, vol. 13, No. 3, pp. 419-432, (2002).
Mehrotra, M. M., et. al., Discovery of Novel 2,8-Diazaspiro[4.5]Decanes as Orally active Glycoprotein lllb-lla Antagonists, J. Med. Chem., (2004), vol. 47, pp. 2037-2061.
Thurmond, R. L., et. al., Cathepsin S Inhibitors as Novel Irnmunomodulators, Curr. Opin. Invest. Drugs. vol. 6, No. 5, pp. 473-482, (2005).
Yasuda, Y., et. al., The Role of Cathepsins in Osteoporosis and Arthritis: Rationale for the Design of New Therapeutics, Advanced Drug Delivery Reviews, vol. 57, (2005), pp. 973-993.
Baici et al, Cathepsin B in Osteoarthritis: Uncontrolled Proteolysis in the Wrong Place, Seminars in Arthritis and Rheumatism (2005) 34(6) Suppl. 2 pp. 24-28.
Abbenante el al. Protease Inhibitors in the Clinic, Medicinal Chemistry (2005) 1 pp. 71-104.
Najer el al, Guanidines douees d'activite antihypertensive, 4e memoire: N-beta-guanidirioethyl azaspiro alcanes, Bull. Soc. Chim, France (Memoires Presentes a la Societe Chimique (1964) pp. 2572-2581, only structures considered.
Bauer Armin
Kohlmann Anna
Schudok Manfred
Wagner Michael
Bender Kelly L.
Jarrell Noble
Sanofi-Aventis
LandOfFree
Spirocyclic nitriles as protease inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Spirocyclic nitriles as protease inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Spirocyclic nitriles as protease inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4274096